IP Library Patent Application 13405087
Patent Application
App. No. 13/405,087

System and Method for Lowering IOP by Creation of Microchannels in Trabecular Meshwork Using a Femtosecond Laser

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/405,087
Filed
Feb 24, 2012
Art Unit
3769
USPC
606/4
Abstract

A system and its method for creating a microchannel in the trabecular meshwork of an eye include a laser unit for generating a laser beam, and an imaging unit for creating an image of the trabecular meshwork. The system also includes a computer which defines the microchannel. A comparator that is connected with the computer then controls the laser unit to move the focal point of the laser beam. This focal point movement is accomplished to create the microchannel, while minimizing deviations of the focal point from the defined microchannel.

Claims (39)

1 . A system for improving the outflow of aqueous fluid from the anterior chamber of the eye to lower the intraocular pressure (IOP) of the eye, the system comprising:

a laser unit for generating a laser beam, and for directing the laser beam along a laser beam path to a focal point in a target tissue to alter the target tissue by Laser Induced Optical Breakdown (LIOB) and establish a fluid flow channel in the target tissue;

an imaging unit for creating an image of the target tissue;

a computer connected to the laser unit, and to the imaging unit, for guiding the focal point of the laser beam in accordance with a predetermined computer program, wherein the computer program defines the fluid flow channel; and

a comparator connected to the imaging unit and to the computer for determining a deviation of the focal point from the defined fluid flow channel to produce an error signal indicative of the deviation, and for moving the focal point to minimize the error signal during creation of the fluid flow channel.

2 . A system as recited in claim 1 wherein the laser beam is a pulsed femtosecond laser beam, and the imaging unit is operated using Optical Coherence Tomography (OCT) techniques.

3 . A system as recited in claim 1 wherein the fluid flow channel is a microchannel extending through the trabecular meshwork, and wherein the microchannel is positioned to interconnect the anterior chamber of the eye in fluid communication with Schlemm's canal.

4 . A system as recited in claim 1 wherein the fluid flow channel is a microchannel extending through the iris of the eye, and wherein the microchannel is positioned to interconnect the posterior chamber of the eye in fluid communication with the anterior chamber of the eye.

5 . A system as recited in claim 1 further comprising:

a contact lens connected to the laser unit; and

a deflecting mirror mounted on the contact lens for directing the laser beam path to the target tissue.

6 . A system as recited in claim 4 wherein the laser beam path is directed to the target tissue through the sclera of the eye.

7 . A closed loop feedback control system for creating a microchannel in a target tissue of an eye which comprises:

a computer with a computer program, wherein the computer program defines the microchannel in the trabecular meshwork for use as a reference input for the system;

a laser unit for generating a laser beam, wherein the laser unit is responsive to an actuating signal from the computer to establish an output for directing the laser beam from the laser unit to a focal point in the target tissue;

an imaging unit for creating an image of the target tissue; and

a comparator for receiving the output from the laser unit, and for receiving the image from the imaging unit, to generate a feedback error signal based on the reference input, wherein the feedback error signal is a measure of a deviation of the focal point of the laser unit from the image of the microchannel created by the imaging unit, and wherein the feedback error signal is used for modifying the actuating signal to the laser unit, with an altered reference input from the computer, to minimize the feedback error signal.

8 . A system as recited in claim 7 wherein the microchannel is established to enhance the functionality of Schlemm's canal by improving the outflow of aqueous fluid from the anterior chamber of the eye in order to lower the intraocular pressure (IOP) of the eye.

9 . A system as recited in claim 7 wherein the imaging unit is an Optical Coherence Tomography (OCT) device.

10 . A system as recited in claim 7 wherein the laser beam is a pulsed femtosecond laser beam.

11 . A system as recited in claim 7 wherein the microchannel extends through the trabecular meshwork, and wherein the microchannel is positioned to interconnect the anterior chamber of the eye in fluid communication with Schlemm's canal.

12 . A system as recited in claim 7 wherein the microchannel extends through the iris of the eye, and wherein the microchannel is positioned to interconnect the posterior chamber of the eye in fluid communication with the anterior chamber of the eye.

13 . A system as recited in claim 7 wherein the laser beam is directed along a laser beam path, and the system further comprises a gonioscope for altering the laser beam path.

14 . A method for creating a microchannel in a target tissue in an eye which comprises the steps of:

generating a laser beam;

directing the laser beam along a laser beam path to a focal point in the target tissue;

guiding the focal point of the laser beam in accordance with a predetermined computer program to alter tissue by Laser Induced Optical Breakdown (LIOB) for creation of the microchannel, wherein the computer program defines the microchannel;

creating an image of the target tissue;

locating a placement for the microchannel in the image;

determining a deviation of the focal point from the image of the microchannel in the target tissue;

producing an error signal indicative of the deviation; and

moving the focal point of the laser beam to minimize the error signal during creation of the microchannel.

15 . A method as recited in claim 14 wherein the laser beam is a pulsed femtosecond laser beam.

16 . A method as recited in claim 14 wherein the microchannel extends through the trabecular meshwork and is positioned to interconnect the anterior chamber of the eye in fluid communication with Schlemm's canal.

17 . A method as recited in claim 16 wherein the microchannel is positioned to enhance the functionality of Schlemm's canal by improving the outflow of aqueous fluid from the anterior chamber of the eye in order to lower the intraocular pressure (IOP) of the eye.

18 . A method as recited in claim 14 wherein the creating step is accomplished by an Optical Coherence Tomography (OCT) device.

19 . A method as recited in claim 14 wherein the performance of the method is controlled by a computer.

20 . A method as recited in claim 14 wherein the laser beam path of the directing step passes through the sclera.

21 . A computer program product comprising program sections for respectively: defining a microchannel in a transparent material; creating an image of the microchannel in the material; directing a laser beam along a laser beam path to a focal point in the material; guiding the focal point to alter material by Laser Induced Optical Breakdown (LIOB) to create the microchannel; determining a deviation of the focal point from the image of the microchannel; producing an error signal indicative of the deviation; and moving the focal point of the laser beam to minimize the error signal during creation of the microchannel.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2012
From: GRANT, ROBERT EDWARD; MORDAUNT, DAVID HAYDN
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 027925/0167 →